Synlogic Inc. - SYBX Total Company Value-to-Revenue Ratio

Synlogic, Inc. (SYBX) - corporate logo

Synlogic, Inc. (SYBX) is currently undergoing rigorous crisis management due to a halt in development. The situation is further complicated by a dependence on global laboratory equipment supplies and the severance of scientific ties. Aggressive pressure from biopharma behemoths in the metabolism sector is further squeezing markets. The EV/Sales valuation multiple clearly demonstrates these risks, and this metric has reached 0.00, reflecting the current market value of the business.

SYBX Synlogic: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 01/24/2026

Financial and market metric breakdowns for Synlogic Corp (SYBX)

- share price and expert price forecast:
Initial company analysis:Synlogic Corp, SYBX
Original product of Synlogic Inc.

This indicator compares the total enterprise value, including net debt, to annual sales, reflecting the market valuation of every dollar of revenue. For Synlogic, Inc. (SYBX), which is developing "living medicine" therapies for the GI tract, the current EV/Sales ratio signals how investors assess the commercialization potential of synthetic bacteria amid fiscal risks and operating margin dynamics.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Enterprise Value-to-Revenue Ratio vtvtherapeutics.com (VTVT)|ATPC (Agape ATP) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Pluristem Therapeutics PLUR|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)